6-APDB

6-APDB, also known as 6-(2-aminopropyl)-2,3-dihydrobenzofuran or as 4-desoxy-MDA, is an entactogen of the phenethylamine, amphetamine, and dihydrobenzofuran families. It is an analogue of MDA where the heterocyclic 4-position oxygen from the 3,4-methylenedioxy ring has been replaced with a methylene bridge. 5-APDB (3-desoxy-MDA) is an analogue of 6-APDB where the 3-position oxygen has been replaced with a methylene instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA and first described in 1993.

Pharmacology

Pharmacodynamics In animal drug discrimination studies, 6-APDB fully substitutes for MBDB and MMAI but not for amphetamine or LSD. In subsequent animal studies, 6-APDB produced robust hyperlocomotion and, in drug discrimination tests, fully substituted for MDMA, partially substituted for DOM and cocaine, and failed to substitute for methamphetamine. ==Chemistry==

Chemistry

6-APDB, also known as 6-(2-aminopropyl)-2,3-dihydrobenzofuran, is a phenethylamine, amphetamine, and dihydrobenzofuran and an analogue of 3,4-methylenedioxyamphetamine (MDA). Synthesis The chemical synthesis of 6-APDB has been described. Analogues In contrast to 6-APDB, 5-APDB is highly selective for serotonin. The unsaturated benzofuran derivative 6-APB, or 6-(2-aminopropyl)benzofuran is also known, but the difference in pharmacological effects between 6-APB and 6-APDB is unclear. ==History==

History

6-APDB, along with 5-APDB, was described by David E. Nichols and colleagues at Purdue University as an MDMA analogue in 1993. Subsequently, the non-dihydrogenated benzofurans 5-APB and 6-APB emerged as novel designer drugs in 2010. Prior to this, 5-APB and 6-APB had been patented and first described by Eli Lilly and Company as serotonin 5-HT2C receptor agonists for potential medical applications in 2000. 5-APB and 6-APB are often confused with 5-APDB and 6-APDB. ==Society and culture==

Society and culture

Legal status Canada 6-APDB is a Schedule I controlled substance in Canada due phenethylamine blanket-ban language. United Kingdom 6-APDB is a class B drug in the United Kingdom since June 10, 2013. It is banned by a blanket law on benzofurans and related compounds. United States 6-APDB is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. ==See also==

Source: Wikipedia ↗

tickerdossier.com tickerdossier.substack.com